The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

Delveinsight

FEBRUARY 16, 2021

The drug is the first and only therapy that is developed and approved to protect bone marrow (myeloprotection), which is injected prior to treatment with chemotherapy, asserts the US oncology drug developer, G1. Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Delveinsight

JANUARY 7, 2021

Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Ikena will back a pipeline that falls into two categories.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil Neuroscience. SciNeuro Pharmaceuticals.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. vice president of immunology development at Lilly. “Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

NOVEMBER 11, 2020

“These data provide further evidence of efficacy and high potency of SLV213 against SARS-CoV-2 and support the clinical development of SLV213 as a potential oral treatment for COVID-19,” said Ted Daley, President and CEO, Selva Therapeutics. “As Viruses work by infecting host cells and hijacking the cell’s replication machinery.

Protein 52

Protein Bioavailability Development Licensing 52